ArticleAnalytical chemistry2015
Centrifugal microfluidic platform for ultrasensitive detection of botulinum toxin.
Article in Analytical chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Microscale Affinity Chromatography for Biointeraction Analysis: Strategies, Principles and Applications.Journal of separation science · 2026Review
- Review
- Antibody-based alternatives to animal testing for toxin detection and antitoxin evaluation.Frontiers in toxicology · 2025Review
- Article
- Pathogenicity and virulence ofVirulence · 2023Review
- Healthy humans can be a source of antibodies countering COVID-19.Bioengineered · 2022Article
- Current Developments in Diagnostic Assays for Laboratory Confirmation and Investigation of Botulism.Journal of clinical microbiology · 2022Review
- Rapid Detection ofInternational journal of environmental research and public health · 2021Article
- Engineered Microsystems for Spheroid and Organoid Studies.Advanced healthcare materials · 2021Review
- Review
- Rapid Detection of Botulinum Neurotoxins-A Review.Toxins · 2019Review
- SERS detection ofAnalytica chimica acta: X · 2019Article
- Ultrasensitive Multi-Species Detection of CRISPR-Cas9 by a Portable Centrifugal Microfluidic Platform.Analytical methods : advancing methods and applications · 2019Article
- Integrated LAMP and immunoassay platform for diarrheal disease detection.Biosensors & bioelectronics · 2018Article
- Article
- Measurement of Carcinoembryonic Antigen in Clinical Serum Samples Using a Centrifugal Microfluidic Device.Micromachines · 2018Article
- Botulinum Neurotoxin Detection Methods for Public Health Response and Surveillance.Frontiers in bioengineering and biotechnology · 2018Review
- Fabrication of a Novel Highly Sensitive and Selective Immunosensor for Botulinum Neurotoxin Serotype A Based on an Effective Platform of Electrosynthesized Gold Nanodendrites/Chitosan Nanoparticles.Sensors (Basel, Switzerland) · 2017Article
- Rapid, Portable, Multiplexed Detection of Bacterial Pathogens Directly from Clinical Sample Matrices.Biosensors · 2016Article
- A Review of Biomedical Centrifugal Microfluidic Platforms.Micromachines · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
We present an innovative centrifugal microfluidic immunoassay platform (SpinDx) to address the urgent biodefense and public health need for ultrasensitive point-of-care/incident detection of botulinum toxin. The simple, sample-to-answer centrifugal microfluidic immunoassay approach is based on binding of toxins to antibody-laden capture particles followed by sedimentation of the particles through a density-media in a microfluidic disk and quantification by laser-induced fluorescence. A blind, head-to-head comparison study of SpinDx versus the gold-standard mouse bioassay demonstrates 100-fold improvement in sensitivity (limit of detection = 0.09 pg/mL), while achieving total sample-to-answer time of <30 min with 2-μL required volume of the unprocessed sample. We further demonstrate quantification of botulinum toxin in both exogeneous (human blood and serum spiked with toxins) and endogeneous (serum from mice intoxicated via oral, intranasal, and intravenous routes) samples. SpinDx can analyze, without any sample preparation, multiple sample types including whole blood, serum, and food. It is readily expandable to additional analytes as the assay reagents (i.e., the capture beads and detection antibodies) are disconnected from the disk architecture and the reader, facilitating rapid development of new assays. SpinDx can also serve as a general-purpose immunoassay platform applicable to diagnosis of other conditions and diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.